

**9 September 2020**

Australian Securities Exchange  
20 Bridge Street  
Sydney NSW 2000

## **FY2020 Results Presentation**

**Melbourne, Victoria** - Alcidion Group Limited (ASX: ALC) today releases the attached FY2020 results investor presentation that will be presented to investors this week by Managing Director Kate Quirke.

Kate Quirke will be conducting a series of 1-1 investor briefings this week, from Wednesday 9<sup>th</sup> September to Friday 11<sup>th</sup> September 2020.

**ENDS**

For further information, please contact:

**Kyahn Williamson**

WE Communications

Ph: +61 401 018 828

[kwilliamson@we-worldwide.com](mailto:kwilliamson@we-worldwide.com)

### **About Alcidion**

Alcidion (ASX:ALC) has a simple purpose: to transform healthcare with smart, intuitive technology solutions that meet the needs of hospital and allied healthcare, worldwide. It offers a complementary set of software products and services that create a unique offering in the global healthcare market; solutions that support interoperability, allow communication and task management, and deliver clinical decision support at the point of care to improve patient outcomes. In 2017 Alcidion acquired Oncall System and its Smartpage clinical communication system. In 2018 it acquired the Patienttrack bedside patient monitoring software and MKM Health, an IT solutions and services provider. These offerings now operate under the Alcidion brand. With over 25 years of combined healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

[www.alcidion.com](http://www.alcidion.com)

© Alcidion Group Limited 2020. Alcidion, Miya Precision, Patienttrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

This announcement is authorised for release by the Board of Directors of Alcidion Limited.

# Investor Presentation


## FY20 Full Year Results Update

Kate Quirke, Group Managing Director  
September 2020



Health informatics company enabling healthcare organisations to utilise technology to transform healthcare delivery

- Unique software & service offering to support safer & smarter healthcare delivery
- Targeting three core geographies:
  - Australia
  - New Zealand
  - United Kingdom



***"Making the right thing to do, the easiest thing to do"***

**307**


**Hospitals**  
Across UK, AUS & NZ

**63**

**Healthcare Organisations**  
Partnering with ALC

**50K**

**Beds**  
Using ALC technology



## Solid growth achieved in FY20 despite a challenging environment

**\$18.6M**

REVENUE DELIVERED IN  
FY2020, 10% INCREASE ON  
FY2019

**\$12.8M**

PRESOLD REVENUE FOR  
FY21, 9% INCREASE ON  
PRIOR YEAR

**35%**

INCREASE IN RECURRING  
REVENUE BASE ON FY2019

**\$16.2M**

RAISED IN NOVEMBER  
2019 TO ACCELERATE  
GROWTH IN ALL MARKETS

**\$15.9M**

CASH RESERVES AT 30 JUNE  
2020

**\$1B+**

GROWING MARKET  
OPPORTUNITY ACROSS  
THREE EXISTING SECTORS

# Supporting healthcare providers through COVID-19

- **COVID-19 pandemic** created significant challenges for healthcare organisations, as providers were forced at short notice to quickly adopt measures to deal with the impact of the virus
- **Some delays in contract signings** in H2 as customer focus shifted, however sales pipeline remains strong & COVID has enabled new opportunities
- **Alcidion moved quickly** to develop new capabilities into Miya Precision & Patientrack to support providers manage the virus
- **Monitoring dashboard** solution developed for Miya Precision, enabling monitoring of COVID-19 patient vital signs, both in-hospital & remotely
- **COVID-19 assessment tool** developed for Patientrack & offered to current customers at no cost, supporting the critical short-term needs of our customers
- **Seamless transition** of Alcidion staff to remote working conditions, with no impact to operations
- **No reduction** in staff or services offered

Customers using Miya Precision for remote monitoring of COVID-19 patients



Health  
Murrumbidgee  
Local Health District



Health  
Sydney  
Local Health District


For personal use only

# Financials


# FY2020 Financial Highlights

- **10% revenue growth** achieved in FY2020 despite challenging environment in second half due to COVID-19
- Recurring revenue base **increased 35%** on prior year
- **Strong cash balance of \$15.9M** at 30 June, well-capitalised to drive further growth in FY2021
- As at 30 June, **\$12.8M sold revenue** is already contracted to be recognised in FY2021, 9% up on last year

**Total sold revenue - YTD**



**Recurring vs non-recurring revenue YTD**





# Profit & Loss (Pro Forma)

Profit & Loss (\$A000s)	FY19	FY20
Recurring	7,824	10,459
Non-recurring	9,040	8,150
<b>Total Revenue</b>	<b>16,864</b>	<b>18,608</b>
Service delivery	(5,537)	(6,174)
Hosting costs	-	(381)
Sales staff + commissions	(1,411)	(2,092)
Product development + support & other	(3,171)	(3,054)
Re-sold Products / Services	(834)	(2,066)
<b>Cost of Sales</b>	<b>(10,953)</b>	<b>(13,767)</b>
<b>Gross Profit</b>	<b>5,912</b>	<b>4,841</b>
Gross profit margin %	35%	26%
Salaries & Wages	(2,649)	(4,136)
Marketing	(636)	(559)
Operations & Admin	(1,134)	(2,224)
Other	(1,531)	(1,694)
<b>Operating Expenses</b>	<b>(5,950)</b>	<b>(8,612)</b>
<b>EBITDA</b>	<b>(39)</b>	<b>(3,771)</b>

FY20 Revenue Split	Services	Prod. Imp	Products	Total
Recurring	1,748	0	8,710	10,459
Non-recurring	2,776	3,674	1,700	8,150
<b>Total Revenue</b>	<b>4,524</b>	<b>3,674</b>	<b>10,410</b>	<b>18,608</b>

## Key Comments

- 10% pcp revenue growth, despite experiencing delays of some contracts as a result of COVID-19 in H2'20
- 56% revenue attributable to Products (Miya Precision, Patientrack, Smartpage) predominantly recurring in the form of licence & maintenance & support fees
  - Licence fees paid upfront are classified as non-recurring, albeit will be paid again on extension or renewal of current contracted licence term
  - Over time expect Products to increase as a percentage of total revenue, underpinning an increasing recurring revenue base
- Gross profit margin % lower than other software-driven healthcare peers due to Cost of Sales incl. several items that others typically show in operating expenses
  - From H1'21 onwards, ALC will begin to report Sales staff & Product Development + support costs within operating expenses
- Service delivery includes Services & Product Implementation
- Reduced FY20 gross profit \$ & margin the result of enlarged sales team which won't generate revenue until FY21 & significantly increased cost of re-sold product which included strategic one-off deal done at low margin
- Large personnel investment in FY20 to bolster management, sales & product development capability to underpin material growth phase
  - Full year impact from H2'20 recruitments are included in planned FY21 strategic investments as well as increased investment in marketing
  - FY20 investments in sales & product expected to accelerate revenue growth from FY21



# Revenue Breakdown

Licence + M&S<sup>1</sup> recurring revenue underpin future growth, supported by implementation & service fees benefiting current cash flow

Core Offering

**Products**

~80%<sup>2</sup>

**Technical Services**

~20%<sup>2</sup>

Key Product /  
Services

Miya Precision, Patientrack, Smartpage  
Reseller products (e.g. Nextgate, OpenEP)

Data analytics, Integration, interoperability  
& technical design

Revenue  
Streams

~60%

**Licence Fees + M&S<sup>2</sup>**



**Implementation Fee**

~20%

**Services Fee**

Revenue  
Model



Recurring



Upfront, one-off



Recurring (approx. 40%)



One-off (approx. 60%)

Nature of  
Contracts

- 3 or 5 year initial contract term
- Renewal options or continued on rolling basis
- Licence fees may be paid annually or upfront for each contracted term

- Required for any new contract
- Typically charged monthly during implementation phase at beginning of contract

- Consistent revenue; fixed price &/or fee for service
- Validates & builds ALC's capability & reputation as a leading authority on hospital IT systems
- Enables initial entry to new customers, building relationship to offer product portfolio

1. M&S = Maintenance & Support

2. Approximate percentage of FY20 revenue; may vary quarter to quarter

# Cash Flow

Cash Flow Statement (A\$000's)	FY19	FY20
<b>Cash flows from operating activities</b>		
Receipts from customers	16,469	20,543
Payments to suppliers and employees	(14,494)	(22,556)
Interest received	16	74
Finance costs and low value lease payments	-	(79)
<b>Net cash inflows (outflows) from operating activities</b>	<b>1,991</b>	<b>(2,017)</b>
<b>Cash flows from investing activities</b>		
Payments for plant and equipment	(265)	(124)
Acquisition of business, net of cash acquired	(1,476)	-
Payment of contingent consideration – Oncall Systems	-	(238)
<b>Net cash (outflows) from investing activities</b>	<b>(1,741)</b>	<b>(362)</b>
<b>Cash flows from financing activities</b>		
Net of proceeds from issues of equity securities	-	15,362
Proceeds from borrowing	92	-
Repayment of principal on lease liabilities – AASB 16	-	(175)
Repayments of borrowings	(61)	(31)
<b>Net cash inflows from financing activities</b>	<b>31</b>	<b>15,155</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>282</b>	<b>12,776</b>
Cash and cash equivalents at the beginning of the year	2,890	3,172
<b>Cash and cash equivalents at the end of the year</b>	<b>3,172</b>	<b>15,948</b>

## Key Comments

- Strong cash balance of \$15.9M at 30 June 2020, raised \$16.2m via Placement in November 2019
- Positive cash conversion cycle – typically receive licence & M&S fees in advance of work being completed which along with regular monthly services fees, allow the Company to scale with less working capital
- 56% increase in payments to suppliers & employees includes:
  - Year end headcount increase from 84 to 114 – due to strategic investment in sales, product development & management
  - Extra payments made for resold third-party products in FY20

For personal use only

# Growth Strategy Update

# FY2020 Operational Highlights

## A year of solid progress – expanded user base, product evolution & scale up

- Growing customer base, with key Miya Precision reference sites across UK, Australia & NZ
- UK scale up underway, key sales & marketing hires in place supporting future growth
- Miya Memory (mobile EMR) & remote patient monitoring launched– successful pilots have led to first contracts
- Investment in digital health a strategic priority for healthcare providers
- Positive outlook – improved base of pre-sold work, healthy sales pipeline, investments for growth to take make impact in FY21

## Significant contracts signed in FY2020



## More signed already in FY2021



# Delivering on our growth strategy

For personal use only

## Accelerate growth in existing markets

- Key hires in Sales & Marketing made in each market
- Solid early results – new contract signings & enhanced sales capability
- UK marketing launch of Miya Precision in September 2020
- Supported by accelerated marketing strategy

## Scale up the business

- Key hires in place to support scale – PPC, Commercial, IT, Quality Management
- Continued development of Miya Precision platform
- Enhanced deployment capabilities to support partner strategy
- Product consolidation created 16 Miya Precision modules to encompass whole product suite – revised website

## Further develop out-of-hospital care

- Development of remote patient monitoring accelerated in response to COVID-19
- Currently in-use at Murrumbidgee LHD & being implemented at Sydney LHD

## Geographic expansion

- Assessment of potential new markets continues
- In COVID-19 environment, priority focus is existing markets
- M&A activity – reviewing market for aligned businesses

## Add distribution channels


- Continued development of partnerships with organisations that may seek to act as distribution channels

# UK Market Update

## Current market presence

18 NHS Trusts

45 Hospitals



■ Total UK beds available

■ Beds using an Alcidion product

## Key reference sites

**NHS**  
Dartford and Gravesham  
NHS Trust

**NHS**  
Manchester University  
NHS Foundation Trust

**NHS**  
Bolton  
NHS Foundation Trust

Basildon and  
Thurrock  
University  
Hospitals **NHS**  
NHS Foundation Trust

**NHS**  
George Eliot Hospital  
NHS Trust

**NHS**  
Fife

**NHS**  
Western Sussex Hospitals  
NHS Foundation Trust

**NHS**  
Derbyshire Healthcare  
NHS Foundation Trust

**NHS**  
Taunton and Somerset  
NHS Foundation Trust

**NHS**  
Lanarkshire

## Market Dynamics

- Government-led investment in digital health as part of NHS reform
- Mix of integrated EMR and Best of Breed solutions
- Increasing frameworks established for efficient digital health procurement

## Progress & Outlook

- Patientrack (Miya Observations) deployed in several "emergency" hospitals at COVID-19 peak
- Market presence expanded via several new contract signings / extensions
- Smartpage added to NHS Clinical Communications Procurement Framework
- New GM Lynette Ousby appointed & restructuring of UK operations
- Major marketing campaign launched in August 2020, Miya Precision launch in September




# Australia Market Update

## Current market presence

33 Customers

236 Hospitals



■ Total AU beds available

■ Beds using an Alcidion product

## Key reference sites



## Market Dynamics

- Healthcare services moving to integrated models of care
- Digital health a core part of investment in integrated care model
- Government digital health spend currently \$2Bn & set to rise

## Progress & Outlook

- Strengthening relationships within NSW Health – Murrumbidgee LHD & Sydney LHD, with opportunity to expand
- ACT Health – now live with Miya Precision, contract extensions signed
- New GM of Sales & Marketing appointed to drive marketing & sales strategy in ANZ
- Growing pipeline around virtual care & adding value to EMR investments




# New Zealand Market Update

## Current market presence

18 District Health Boards

45 Hospitals



■ Total NZ beds available

■ Beds using an Alcidion product

## Key reference sites



**MIDCENTRAL DISTRICT HEALTH BOARD**  
Te Pae Hauora o Ruahine o Tararua

TE MAIORA

**Nelson Marlborough Health**



**Waitemata**  
District Health Board  
Best Care for Everyone



**Capital & Coast**  
District Health Board  
ŪPOKO KI TE URU HAUORA




**West Coast**  
— District Health Board —  
Te Poari Hauora a Rohe o Tai Poutini

**South Canterbury**  
District Health Board

**Canterbury**

District Health Board  
Te Poari Hauora o Waitaha



**COUNTIES MANUKAU**  
HEALTH

## Market Dynamics

- Miya Observations & Assessments clear market leader for patient observations in South Island & Northern Region DHBs
- Best of Breed solutions more commonly used over EMRs
- Integration & interoperability a key driver

## Progress & Outlook

- Benefit from new sales appointments for ANZ region
- Smartpage adopted at Nelson DHB & trial underway at Counties Manukau DHB
- Opportunity to add Miya Precision modules to existing customers, in-line with digital transformation needs
- All of healthcare sector review has signalled future investment in digital health in improving data driven decision making

For personal use only

# Outlook


# Poised for growth in FY2021

- Cash reserves of \$15.9M at 30 June 2020 to support planned investment, cost base to stabilise in FY21
- \$12.8M sold revenue already contracted to be recognised in FY21 – 9% increase on prior year
- Further \$17.0M sold out to FY2025
- Repositioned product suite supporting expanded sales capabilities in the UK & ANZ
- Strong pipeline of potential business despite some short-term delays to signed contracts


## FY2021

Sold revenue as at  
30 June 2020

Recurring vs Non-  
recurring (\$M)



Products vs Services (\$M)




**Total  
FY21  
\$12.8M**


## FY2020

Sold revenue as at  
30 June 2019 (PCP)

Recurring vs Non-  
Recurring (\$M)



Products vs Services (\$M)



**Total  
FY20  
\$11.7M**

# Disclaimer

This presentation has been prepared by Alcidion Group Limited ('Alcidion'). The information in this presentation is of a general nature and does not purport to be complete, nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act. This presentation may contain statements, opinions, projections, forecasts and other material (forward looking statements), based on various assumptions. Those assumptions may or may not prove to be correct. None of Alcidion, its respective officers, employees, agents, advisers or any other person named in this presentation makes any representation as to the accuracy or likelihood of fulfilment of any forward looking statements or any of the assumptions upon which they are based.

The information contained in this presentation does not take into account the investment objectives, financial situation or particular needs of any recipient and is not financial product advice. Before making an investment decision, recipients of this presentation should consider their own needs and situation and, if necessary, seek independent, professional advice.

To the extent permitted by law, Alcidion and its respective officers, employees, agents and advisers give no warranty, representation or guarantee as to the accuracy, completeness or reliability of the information contained in this presentation. Further, none of Alcidion and its respective officers, employees, agents and advisers accept, to the extent permitted by law, responsibility for any loss, claim, damages, costs or expenses arising out of, or in connection with, the information contained in this presentation. Any recipient of this presentation should independently satisfy themselves as to the accuracy of all information contained herein.

## Contacts

**Kyahn Williamson**

Group Head: Corporate and Investor  
Communication  
WE Communications

[kwilliamson@we-worldwide.com](mailto:kwilliamson@we-worldwide.com)

+61 401 018 828